Welcome to our dedicated page for Sionna Therapeutics SEC filings (Ticker: SION), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sionna Therapeutics, Inc. (Nasdaq: SION) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Sionna describes itself as a clinical-stage biopharmaceutical company focused on developing CFTR-targeted therapies for cystic fibrosis, and its filings offer detail on this business and its financial position.
Among the key documents available are current reports on Form 8-K, where Sionna furnishes press releases announcing quarterly financial results and business highlights. For example, the company has used Form 8-K to present information on research and development expenses, general and administrative expenses, net loss, cash and cash equivalents, and progress across its clinical pipeline of NBD1 stabilizers and complementary CFTR modulators.
In addition to 8-Ks, investors typically look to annual reports on Form 10-K and quarterly reports on Form 10-Q for broader discussions of risk factors, research and development activities, and the company’s focus on cystic fibrosis therapies. These filings can also describe Sionna’s status as an emerging growth company, its operating segment dedicated to CF drug development, and other structural aspects of the business.
Stock Titan enhances access to SION filings by pairing real-time updates from the EDGAR system with AI-powered summaries that explain the significance of each document in clear language. Users can quickly identify items related to clinical trial progress, financial condition, and other material events, and can review insider and management-related disclosures where applicable. This page serves as a central location for reviewing Sionna’s regulatory history and understanding how its CF-focused strategy is reflected in formal SEC documents.
Sionna Therapeutics director-affiliated fund reports share sale. An entity associated with director Peter A. Thompson, OrbiMed Private Investments VIII, LP, sold 85,918 shares of Sionna Therapeutics common stock in an open-market transaction at $44.86 per share pursuant to a Rule 10b5-1 plan. Following the sale, the entity continues to hold 2,469,959 shares indirectly. OrbiMed-related entities and the reporting person may be deemed to have beneficial ownership through control relationships but each disclaims beneficial ownership beyond any pecuniary interest.
ORBIMED ADVISORS LLC and OrbiMed Capital GP VIII LLC, reporting as directors of Sionna Therapeutics, Inc., reported an indirect open‑market sale of common stock. On July 7, 2026, an affiliated investment fund sold 85,918 shares of Sionna common stock at $44.86 per share.
The sold shares are held of record by OrbiMed Private Investments VIII, LP, for which OrbiMed Capital GP VIII LLC is the general partner and OrbiMed Advisors LLC is the managing member. Following this sale, indirect holdings reported for the OrbiMed entities totaled 2,469,959 shares of Sionna common stock. The sale was executed under a Rule 10b5-1 trading plan, and the reporting persons disclaim beneficial ownership of the securities except to the extent of any pecuniary interest.
Sionna Therapeutics, Inc. Chief Legal Officer Jennifer Fitzpatrick reported an exercise-and-sell transaction involving company common stock. She exercised options to acquire 10,250 shares of common stock at an exercise price of $6.11 per share and sold the same 10,250 shares in an open-market transaction at a weighted-average price of $43.5963 per share. The filing states that this sale was automatically executed under a Rule 10b5-1 trading plan adopted on June 5, 2025. Following these transactions, the report shows she holds no shares of common stock directly. The underlying option grant vested 25% on June 3, 2025, with the remainder vesting in thirty-six equal monthly installments, subject to continued service.
Sionna Therapeutics director-affiliated fund reports planned share sale. OrbiMed Private Investments VIII LP, an entity associated with director Peter A. Thompson, sold 115,844 shares of Sionna Therapeutics common stock in an open-market transaction at $45.50 per share under a Rule 10b5-1 trading plan. Following this sale, 2,555,877 shares of Sionna common stock are reported as indirectly held, with OrbiMed-related entities and the reporting person disclaiming beneficial ownership beyond any pecuniary interest.
OrbiMed-affiliated entities reported an open-market sale of Sionna Therapeutics stock under a pre-arranged trading plan. An entity associated with OrbiMed sold 115,844 shares of Sionna Therapeutics, Inc. common stock at a price of $45.50 per share pursuant to a Rule 10b5-1 plan. After this transaction, the OrbiMed-related holder continues to own 2,555,877 shares indirectly through OrbiMed Private Investments VIII, LP, reflecting a large remaining position. OrbiMed Capital GP VIII LLC and OrbiMed Advisors LLC may be deemed to share voting and investment power over these shares, but they each disclaim beneficial ownership beyond any pecuniary interest.
Sionna Therapeutics director Laurie Stelzer received a grant of non-qualified stock options covering 17,340 shares of common stock. The options have an exercise price of $36.73 per share and expire on June 16, 2036.
The option vests in full on the earlier of June 17, 2027 or the date of Sionna Therapeutics’ next annual meeting, subject to her continued service. Following this grant, Stelzer holds options for 17,340 underlying shares directly, reflecting a routine equity-based compensation award rather than an open-market share purchase or sale.
Sionna Therapeutics director Joanne L. Viney received a grant of a non-qualified stock option covering 17,340 shares of common stock. The option has an exercise price of $36.73 per share and expires on June 16, 2036.
The option vests in full on the earlier of June 17, 2027 or the date of Sionna’s next annual meeting, subject to her continued service as a director. Following this award, she holds options representing the right to acquire 17,340 shares directly. This is a compensation-related award, not an open-market purchase or sale.
Sionna Therapeutics director Peter A. Thompson reported a grant of 17,340 non-qualified stock options linked to Sionna Therapeutics, Inc. common stock. The options have an exercise price of $36.73 per share and expire on June 16, 2036. They vest in full on the earlier of June 17, 2027 or the date of the next annual meeting of Sionna Therapeutics, Inc., contingent on his continued service. Under an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VIII LLC, any securities or economic benefits from these options are to be transferred so that the economic benefit is provided to OrbiMed Private Investments VIII, LP.
Sionna Therapeutics, Inc. reported a Form 4 showing a grant of a non-qualified stock option covering 17,340 shares of common stock. The option has an exercise price of $36.73 per share and expires on June 16, 2036.
According to the footnotes, Dr. Resnick holds this option for the benefit of RA Capital-managed vehicles, and any net cash or stock from exercise will offset advisory fees owed to those funds. RA Capital Management, affiliated funds, and their principals disclaim beneficial ownership of the option and underlying shares except for any pecuniary interest.